Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caplacizumab plus immunosuppressive therapy without first-line plasma exchange in adults with immune-mediated thrombotic thrombocytopenic purpura
2022-001177-31Phase 3Active
- Sponsor
- Sanofi
- Start
- May 2022
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of caplacizumab in thrombotic thrombocytopenic purpura (TTP), sponsored by Sanofi. Primary endpoint: Proportion of participants achieving remission without requiring therapeutic plasma exchange. Started May 2022; status: active.
02
Drugs
caplacizumab
03
Conditions
thrombotic thrombocytopenic purpura (TTP)
Beyond the preview
Go deeper on 2022-001177-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001177-31.